Sood S L, Balaraman V, Finn K C, Britton B, Uyehara C F, Easa D
Department of Pediatrics, Kapiolani Medical Center for Women and Children, John A. Burns School of Medicine, Honolulu, Hawaii 96826, USA.
Am J Respir Crit Care Med. 1996 Feb;153(2):820-8. doi: 10.1164/ajrccm.153.2.8564138.
Evidence for surfactant dysfunction in acute respiratory distress syndrome (ARDS) suggests a role for exogenous surfactant which contains apoprotein for resistance to protein inhibition. We compared the effects of KL-4-Surfactant, an artificial preparation containing a synthetic 21 amino acid peptide with SP-B-like activity, with Exosurf, an artificial protein-free surfactant, and Survanta, a bovine protein-containing surfactant, in a saline lung lavage model of ARDS in neonatal piglets. Two sequential series of lung lavages were performed to lower PaO2 < 100 mm Hg, each followed by administration of surfactant or air and a 90-min observation period. Progressive lung injury was demonstrated by deterioration in pulmonary function, increasing bronchoalveolar lavage protein, and changes in histopathology. All surfactants improved oxygenation, although oxygenation was generally better with Survanta and KL-4-Surfactant. Further, Survanta and KL-4-Surfactant groups showed improvement in ventilation, with decreases in PaCO2 and increases in FRC. Only KL-4-Surfactant demonstrated greater pressure-volume characteristics and lower bronchoalveolar protein than those of Controls. We conclude that the physiologic effects of KL-4-Surfactant are more like Survanta in this model. We speculate that KL-4-Surfactant may improve pulmonary function, reduce alveolar protein leak, and thus be efficacious in the treatment of ARDS.
急性呼吸窘迫综合征(ARDS)中表面活性剂功能障碍的证据表明,含有抗蛋白抑制载脂蛋白的外源性表面活性剂具有一定作用。我们在新生仔猪ARDS的盐水肺灌洗模型中,比较了KL-4表面活性剂(一种含有具有SP-B样活性的合成21氨基酸肽的人工制剂)、Exosurf(一种无蛋白人工表面活性剂)和Survanta(一种含牛蛋白表面活性剂)的效果。进行了两个连续系列的肺灌洗以降低动脉血氧分压(PaO2)<100 mmHg,每次灌洗后给予表面活性剂或空气,并观察90分钟。肺功能恶化、支气管肺泡灌洗蛋白增加和组织病理学变化证明了进行性肺损伤。所有表面活性剂均改善了氧合,尽管Survanta和KL-4表面活性剂的氧合通常更好。此外,Survanta和KL-4表面活性剂组的通气有所改善,动脉血二氧化碳分压(PaCO2)降低,功能残气量(FRC)增加。只有KL-4表面活性剂表现出比对照组更大的压力-容积特性和更低的支气管肺泡蛋白。我们得出结论,在该模型中,KL-4表面活性剂的生理作用更类似于Survanta。我们推测,KL-4表面活性剂可能改善肺功能,减少肺泡蛋白渗漏,从而有效治疗ARDS。